Merotocin

Chemical compound
  • None
Identifiers
  • (3R,6S,9S,12S,15S)-6-(2-Amino-2-oxoethyl)-N-[2-[[(2S)-1-[(2-amino-2-oxoethyl)amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]-9-(3-amino-3-oxopropyl)-12-[(2S)-butan-2-yl]-N-[(4-fluorophenyl)methyl]-15-[(4-hydroxyphenyl)methyl]-5,8,11,14,17-pentaoxo-1-thia-4,7,10,13,16-pentazacycloicosane-3-carboxamide
CAS Number
  • 1190083-57-8
PubChem CID
  • 76073634
ChemSpider
  • 34994563
UNII
  • UW3ON116CO
Chemical and physical dataFormulaC48H68FN11O12SMolar mass1042.20 g·mol−13D model (JSmol)
  • Interactive image
  • CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSCCCC(=O)N[C@H](C(=O)N1)Cc2ccc(cc2)O)C(=O)N(Cc3ccc(cc3)F)CC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N
InChI
  • InChI=1S/C48H68FN11O12S/c1-5-27(4)42-47(71)56-32(16-17-37(50)62)44(68)57-35(21-38(51)63)45(69)58-36(25-73-18-6-7-40(65)54-34(46(70)59-42)20-28-10-14-31(61)15-11-28)48(72)60(23-29-8-12-30(49)13-9-29)24-41(66)55-33(19-26(2)3)43(67)53-22-39(52)64/h8-15,26-27,32-36,42,61H,5-7,16-25H2,1-4H3,(H2,50,62)(H2,51,63)(H2,52,64)(H,53,67)(H,54,65)(H,55,66)(H,56,71)(H,57,68)(H,58,69)(H,59,70)/t27-,32-,33-,34-,35-,36-,42-/m0/s1
  • Key:PVVHQWISMVJHFK-NIFJBHDKSA-N

Merotocin (INN) (developmental code name FE-202767), also known as carba-1-(4-FBzlGly7)dOT, is a peptidic agonist of the oxytocin receptor that was derived from oxytocin.[1][2][3] It is under development by Ferring Pharmaceuticals for the treatment of preterm mothers with lactation failure requiring lactation support, and is in phase II clinical trials for this indication.[3] Merotocin is potent (EC50 < 0.1 nM) and highly selective (>1000-fold over the related vasopressin receptors).

See also

References

  1. ^ Manning M, Misicka A, Olma A, Bankowski K, Stoev S, Chini B, Durroux T, Mouillac B, Corbani M, Guillon G (2012). "Oxytocin and vasopressin agonists and antagonists as research tools and potential therapeutics". Journal of Neuroendocrinology. 24 (4): 609–28. doi:10.1111/j.1365-2826.2012.02303.x. PMC 3490377. PMID 22375852.
  2. ^ Yang Y, Li H, Ward R, Gao L, Wei JF, Xu TR (2014). "Novel oxytocin receptor agonists and antagonists: a patent review (2002 - 2013)". Expert Opinion on Therapeutic Patents. 24 (1): 29–46. doi:10.1517/13543776.2014.845168. PMID 24094047. S2CID 10584554.
  3. ^ a b Wiśniewski K, Alagarsamy S, Galyean R, Tariga H, Thompson D, Ly B, Wiśniewska H, Qi S, Croston G, Laporte R, Rivière PJ, Schteingart CD (2014). "New, potent, and selective peptidic oxytocin receptor agonists". J. Med. Chem. 57 (12): 5306–17. doi:10.1021/jm500365s. PMID 24874785.

External links

  • Pipeline - Ferring Pharmaceuticals
  • Merotocin - AdisInsight


  • v
  • t
  • e
Oxytocin
Vasopressin
V1A
V1B
  • Ligands: TASP-699
V2
Unsorted
  • Antagonists: Balovaptan
  • Ribuvaptan
  • RWJ-339489
  • VMAX-367
  • VMAX-372
  • VMAX-382
  • YM-222546
Others


Stub icon

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

  • v
  • t
  • e